Advanced search
Publication Cover
Expert Review of Pharmacoeconomics & Outcomes Research Volume 9, 2009 - Issue 6
Submit an article Journal homepage
96
Views
7
CrossRef citations to date
0
Altmetric
Review

Reimbursement agency requirements for health related quality-of-life data: a case study

Andrew Lloyd Oxford Outcomes Ltd, Seacourt Tower, West Way, Oxford OX2 0JJ, UK. [email protected]
,
Diane Wild Oxford Outcomes Ltd, Seacourt Tower, West Way, Oxford OX2 0JJ, UK
,
Katy Gallop Oxford Outcomes Ltd, Seacourt Tower, West Way, Oxford OX2 0JJ, UK
&
Warren Cowell Bayer plc, Hunton House, Oxford Road, Uxbridge, Middlesex UB8 IHU, UK
Pages 527-537 | Published online: 09 Jan 2014

References

  • Drummond M, Sculpher MJ, Torrance GW, O’Brien BJ, Stoddart GL. Methods for the Economic Evaluation of Health Care Programmes (3rd edition). Oxford University Press, Oxford, UK (2005).
  • Brazier J, Czoski-Murray C, Roberts J, Brown M, Symonds T, Kelleher C. Estimation of a preference-based index from a condition-specific measure: the King’s Health Questionnaire. Med. Decis. Making28, 113–126 (2008).
  • Clarke P, Gray A, Holman R. Estimating utility values for health states of Type 2 diabetic patients using the EQ-5D (UKPDS 62). Med. Decis. Making22(4), 340–349 (2002).
  • Sullivan P, Ghushchyan V. Preference-based EQ-5D index scores for chronic conditions in the United States. Med. Decis. Making26, 410–420 (2006).
  • National Institute for Health and Clinical Excellence. Guide to the Methods of Technology Appraisal. NICE, London, UK (2008).
  • Scottish Medicines Consortium Guidance to Manufacturers for Completion of New Product Assessment Form (NPAF). Scottish Medicines Consortium. Glasgow, Scotland, UK (2007).
  • Canadian Agency for Drugs and Technologies in Health. Guidelines for the Economic Evaluation of Health Technologies: Canada (3rd edition). Canadian Agency for Drugs and Technologies in Health. ON, Canada (2006).
  • Läkemedelsförmånsnämnden. General Guidelines for Economic Evaluations from the Pharmaceutical Benefits Board. Läkemedelsförmånsnämnden, Solna, Sweden (2003).
  • Pharmaceutical Benefits Advisory Committee. Guidelines for Preparing Submissions to the Pharmaceutical Benefits Advisory Committee (Version 4.2). Pharmaceutical Benefits Advisory Committee, Canberra, Australia (2007).
  • Burström K, Johannesson M, Diderichsen F. A comparison of individual and social time trade-off values for health states in the general population. Health Policy76, 359–370 (2006).
  • Lundberg L, Johannesson M, Isacson DG, Borgquist L. The relationship between health-state utilities and the SF-12 in a general population. Med. Decis. Making19(2), 128–140 (1999).
  • Institute for Quality and Efficiency in Health Care. Methods for Assessment of the Relation of Benefits to Costs in the German Statutory Healthcare System. Institute for Quality and Efficiency in Health Care, Cologne, Germany (2008).
  • Van Exel NJA, Reimer S, Koopmanschap MA. Assessment of post-stroke quality of life in cost–effectiveness studies: the usefulness of the Barthel Index and EuroQoL-5D. Qual. Life Res.13(2), 427–433 (2004).
  • Dorman P, Dennis M, Sandercock P. Are the modified “simple questions” a valid and reliable measure of health related quality of life after stroke? J. Neurol. Neurosurg. Psychiatry69(4), 487–493 (2000).
  • Grootendorst P, Feeny D. Furlong W. Health Utilities Index Mark 3: evidence of construct validity for stroke and arthritis in a population health survey. Med. Care38(3), 290–299 (2000).
  • Hallan S, Asberg A, Indredavik B, Wideroe TE. Quality of life after cerebrovascular stroke: a systematic study of patients’ preferences for different functional outcomes. J. Intern. Med.246(3), 309–316 (1999).
  • Glick HA, Polsky D, Willke RJ, Schulman KA. A comparison of preference assessment instruments used in a clinical trial. Med. Decis. Making19(3), 265–275 (1999).
  • Kind P, Macran S. Eliciting social preference weights for Functional Assessment of Cancer Therapy – Lung health states. Pharmacoeconomics23(11), 1143–1153 (2005).
  • Ader R, Cohen N. Behaviorally conditioned immunosuppression. Psychosomatic Med.37, 333–340 (1975).
  • Bojke L, Claxton K, Sculpher MJ, Palmer S. Identifying research priorities: the value of information associated with repeat screening for age-related macular degeneration. Med. Decis. Making28, 33–43 (2008).
  • Macran S. The Relationship Between Body Mass Index and Health-Related Quality of Life. (Discussion Paper 190). Centre for Health Economics, University of York, York, UK (2004).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.